Last reviewed · How we verify
Tezepelumab Dose 1
At a glance
| Generic name | Tezepelumab Dose 1 |
|---|---|
| Also known as | AMG 157 |
| Sponsor | Amgen |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Phase 3b Study in Patients With Severe Asthma Treated With Tezepelumab (PHASE3)
- Open-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma. (PHASE3)
- A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007) (PHASE3)
- A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006) (PHASE3)
- Observational Study on the Clinical Profile of Patients With Uncontrolled Severe Asthma Treated With Tezepelumab in Italy
- A Comparative Phase 1 Study to Evaluate the Pharmacokinetic and Safety of QL2302 vs. Tezspire® in Healthy Subjects (PHASE1)
- Efficacy of Tezepelumab in Peanut Oral Immunotherapy (PHASE2)
- Study to Evaluate Tezepelumab in Adults With Chronic Spontaneous Urticaria (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tezepelumab Dose 1 CI brief — competitive landscape report
- Tezepelumab Dose 1 updates RSS · CI watch RSS
- Amgen portfolio CI